Ruipu Biotech announced on the morning of July 21 that the company's holding subsidiary, Inner Mongolia Biwei Antai Biotechnology Co., Ltd. recently received the “Veterinary Drug Product Approval Document” issued by the Ministry of Agriculture and Rural Affairs. Biwei Antai's “Bovine and Sheep Foot and Mouth Disease O, Type A, and South Africa Type 1 Trivalent Inactivated Vaccine” and “Pig Foot and Mouth Disease Type O and South Africa Type 1 Bivalent Inactivated Vaccine” were approved for production. The two products have been approved for production, which will further enrich the company's foot-and-mouth disease vaccine product pipeline and meet domestic market demand for the prevention and control of the latest foot-and-mouth disease strain.

Ruipu Biotech announced on the morning of July 21 that the company's holding subsidiary, Inner Mongolia Biwei Antai Biotechnology Co., Ltd. recently received the “Veterinary Drug Product Approval Document” issued by the Ministry of Agriculture and Rural Affairs. Biwei Antai's “Bovine and Sheep Foot and Mouth Disease O, Type A, and South Africa Type 1 Trivalent Inactivated Vaccine” and “Pig Foot and Mouth Disease Type O and South Africa Type 1 Bivalent Inactivated Vaccine” were approved for production. The two products have been approved for production, which will further enrich the company's foot-and-mouth disease vaccine product pipeline and meet domestic market demand for the prevention and control of the latest foot-and-mouth disease strain.